These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28416766)

  • 1. Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.
    Zhang H; Liu L; Liu C; Pan J; Lu G; Zhou Z; Chen Z; Qian C
    Oncotarget; 2017 May; 8(21):34362-34373. PubMed ID: 28416766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
    Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
    Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion.
    Garg M; Kanojia D; Seth A; Kumar R; Gupta A; Surolia A; Suri A
    Eur J Cancer; 2010 Jan; 46(1):207-15. PubMed ID: 19914824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
    Pinazza M; Ghisi M; Minuzzo S; Agnusdei V; Fossati G; Ciminale V; Pezzè L; Ciribilli Y; Pilotto G; Venturoli C; Amadori A; Indraccolo S
    Oncogene; 2018 Jul; 37(28):3839-3851. PubMed ID: 29643474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
    Schlütermann D; Skowron MA; Berleth N; Böhler P; Deitersen J; Stuhldreier F; Wallot-Hieke N; Wu W; Peter C; Hoffmann MJ; Niegisch G; Stork B
    Urol Oncol; 2018 Apr; 36(4):160.e1-160.e13. PubMed ID: 29276062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.
    Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama S; Otsuki Y; Miyazaki K
    Am J Clin Pathol; 2012 Oct; 138(4):535-44. PubMed ID: 23010708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
    Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
    BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.
    Hagiwara M; Kikuchi E; Tanaka N; Kosaka T; Mikami S; Saya H; Oya M
    BMC Cancer; 2018 Jan; 18(1):113. PubMed ID: 29385995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between NOTCH3 expression and the clinical outcome in the urothelial bladder cancer patients.
    Ristic Petrovic A; Stokanović D; Stojnev S; Potić Floranović M; Krstić M; Djordjević I; Skakić A; Janković Veličković L
    Bosn J Basic Med Sci; 2022 Jul; 22(4):523-530. PubMed ID: 35073251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
    Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
    Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
    Zhang Z; Zhang G; Kong C
    Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
    Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
    Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
    Eto S; Saeki K; Yoshitake R; Yoshimoto S; Shinada M; Ikeda N; Kamoto S; Tanaka Y; Kato D; Maeda S; Tsuboi M; Chambers J; Uchida K; Nishimura R; Nakagawa T
    PLoS One; 2019; 14(6):e0218382. PubMed ID: 31206526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3.
    Zou B; Wang H; Liu Y; Qi P; Lei T; Sun M; Wang Y
    Oncol Rep; 2017 Sep; 38(3):1431-1441. PubMed ID: 28714011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
    Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased REG1α expression suppresses growth, invasion and angiogenesis of bladder cancer.
    Geng J; Fan J; Wang Q; Zhang XP; Kang L; Li QY; Xu YF; Peng B; Zheng JH; Yao XD
    Eur J Surg Oncol; 2017 Apr; 43(4):837-846. PubMed ID: 28209239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.
    Kashiwagi E; Inoue S; Mizushima T; Chen J; Ide H; Kawahara T; Reis LO; Baras AS; Netto GJ; Miyamoto H
    Br J Cancer; 2018 Jan; 118(2):213-223. PubMed ID: 29123257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.